The FDA has approved Zusduri (mitomycin intravesical solution) to treat adults with recurrent, low-grade, intermediate-risk NMIBC.

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...

Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...

HHS Secretary Robert F. Kennedy Jr has named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

The Clinical Advisor spoke with Carlos Gutiérrez, EdD, MMS, PA-C, about the impact of executive orders on LGBTQ+ health care.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.